Post

Limited innovation in the late-stage pipeline for insomnia

Insomnia is the most common sleep disorder, characterised by patient-reported difficulty with sleep initiation and/or sleep maintenance. According to the …

Regeneron’s linvoseltamab shows early and durable response in pre-treated MM

Regeneron Pharmaceuticals has presented Phase II data for linvoseltamab in patients with relapsed/refractory (r/r) multiple myeloma (MM) who have received …

Q&A: ‘Trial failure due to recruitment is a thing of the past thanks to AI’

One pain point for sponsors is trial termination due to lack of recruitment, partially a result of recruiting the wrong …

PercAssist implants first patient with extravascular cardiac assistance device

PercAssist has completed its first patient case in its First-in-Human clinical study investigating its Percutaneous Synchronised Cardiac Assist (PSCA) device …

Janssen’s NSCLC combo therapy meets primary endpoint in Phase III trial

The Janssen Pharmaceutical Companies of Johnson & Johnson has reported that the Phase III MARIPOSA clinical trial of Rybrevant (amivantamab-vmjw) …